Current GLP-1 Lawsuit Status (2026): Active Cases, Investigations & What’s Happening Now

This page provides a plain-English snapshot of the current status of GLP-1 drug litigation. Because large pharmaceutical cases evolve over time, this hub is designed to be updated regularly as filings, court coordination, and settlement discussions develop.

Overview: Where GLP-1 Litigation Stands Now

As of 2026, GLP-1 drug litigation is in an active investigation and litigation and early case-building phase, with:

growing numbers of individual claims
coordinated legal review across jurisdictions
increasing focus on severe gastrointestinal and organ injuries, NAION and Vision loss
expanding expert and scientific analysis
itigating the consolidated proceedings in state and federal court

GLP-1 Lawsuit status update, March 29th, 2026

There have been no reported GLP-1 lawsuit settlements. There has been no global settlement of GLP-1 lawsuits
There are no Ozempic class action lawsuits in the United States. There is no GLP-1 class action lawsuit. The lawsuits are Multidistrict litigation in Federal Court (United States District Court, Eastern District of Pennsylvania) and Multicounty litigation in New Jersey State Court. It is unclear why lay people describe GLP litigation as an “Ozempic class action lawsuits.”
Also, there have been no individual trials in the MDL litigations. These trials in legal parlance are known as “bellwether trials.” Outcomes of trials and settlements will depend on how courts and parties proceed as well as court rulings.
Claims pertaining to Ozempic and assorted GLP-1 medications have been delegated to two cohorts in two separate multidistrict litigations (MDL). This should assist the court in to expediting the litigation process. One focuses on gastroparesis, with the other focusing on vision loss.
There are now 3,417 GLP-1 lawsuits in both MDLs as of March 2, 2026.
Judge Karen S. Marston (U.S. District Judge) is presiding over both MDL #3094 (Gastrointestinal problems) and MDL #3163 (Vision loss / NAION)
3363 lawsuits pending in MDL #3094 – “IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation”
54 GLP-1 lawsuits pending in MDL #3163- “IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation.”
There are also 2 Multicounty Litigations pending in New Jersey State Court. One litigation focuses on gastrointestinal problems while the other pertains to vision loss.
Status of Ozempic label: In January 2025, the FDA updated the Ozempic label to include that it is “not recommended in patients with severe gastroparesis.” However, the amended label fo whatever reason does not state that the medication itself could lead to gastroparesis. In September of 2023, the FDA amended the Ozempic label to include Ileus
All predictions of potential Ozempic lawsuit settlement amounts are only speculative guesstimates at this point in time.

February 3, 2026 – Streamlined protocal for vision loss and NAION lawsuits in the federal eye damage MDL

The United States District Judge in charge of the GLP-1 MDL lawsuits, pertaining to VISION LOSS, set forth protocol intended to make the MDL more efficient. Instead of filing new lawsuits in various U.S. District Courts across the U.S., new GLP-1 lawsuits may be e-filed directly in the vision loss multidistrict litigation. This will prevent unnecessary delays concerning transferring GLP-1 lawsuits. This new protocol will allow Ozempic law firms and the Judiciary to efficiently manage the rapidly growing Ozempic lawsuits. (It cannot be emphasized enough that these lawsuits are not Ozempic class action lawsuits nor are they GLP-1 class action lawsuits.)

December 17, 2025 –

The U.S. Judicial Panel on Multidistrict Litigation, which oversees and manages all mass tort litigation in federal courts in the United States, established a separate Federal Court Multi-district litigation (MDL) for GLP-1 vision loss lawsuits. This is a separate MDL than the GLP-1 digestive complications MDL. Both the GLP-1 vision loss MDL and the gastrointestinal side effects MDL will be pending in Pennsylvania Federal Court before Judge Karen Marston.

2024 –

JAMA Ophthalmology engaged in a comprehensive study in 2024 delineating that people suffering through Type 2 diabetes with a semaglutide prescription-such as Wegovy or Ozempic had a fourfold greater risk for a non-arteritic anterior ischemic optic neuropathy (NAION) diagnosis as compared to people not prescribed a GLP-1 agonist. Obese patients had a 7 times greater likelihood of a NAION diagnosis.

Types of Cases Being Filed

Current GLP-1 filings and investigations generally fall into these categories:

Severe GI motility injuries (gastroparesis, bowel obstruction)
Pancreatitis (acute and recurring)
Kidney injury and kidney failure (often dehydration-related)
Gallbladder disease and gallbladder removal
Permanent or long-term digestive disability
Vision Loss & Blindness Claims (NAION) – Vision loss claims are not grouped with GI injury cases and are proceeding under a distinct MDL structure.

These cases typically involve hospitalization, surgery, or lasting impairment.

➡️ Injury hubs:

Are Cases Consolidated Yet?

Large pharmaceutical cases often move toward coordinated proceedings, such as:

federal multidistrict litigation (MDL)
state-level coordinated dockets
hybrid mass-tort structures

At this stage, courts may still be:

reviewing motions
assessing injury commonality
evaluating scientific overlap
determining whether consolidation is appropriate

This phase can take time and does not mean claims are stalled.

What “Early Litigation Phase” Means for Claimants

An early-phase status usually means:

claims are being filed and preserved
medical evidence is being collected
experts are reviewing injury patterns
defendants are assessing exposure
courts are organizing procedures

For claimants, this is often the best time to enter, because eligibility and documentation can be established before frameworks are finalized.

Regulatory & Safety Context

Adverse event reporting and post-marketing surveillance continue to inform litigation. Data from sources such as U.S. Food and Drug Administration adverse-event systems and medical literature are often reviewed by experts to assess injury patterns and warning adequacy.

➡️ Safety trend page: Thousands of Side Effects Reports

What Has Not Happened Yet (Common Misconceptions)

At this stage:

❌ no universal settlement exists
❌ no automatic payouts are occurring
❌ no deadlines are “paused” for everyone
❌ no final rulings on liability have been issued

Waiting for headlines can risk missing filing deadlines or weakening documentation.

Why Early Participation Can Matter

Entering early may help with:

preserving statute-of-limitations rights
securing medical records before loss
inclusion in future settlement frameworks
proper injury categorization
avoiding rushed documentation later

➡️ Time limits: Statute of Limitations

How Status Changes Are Typically Announced

Litigation status updates often occur when:

courts issue consolidation orders
bellwether cases are selected
expert rulings are released
settlement negotiations are confirmed

This page will be updated as those events occur.

What Claimants Should Do Right Now

If you believe you were injured:

Start a case review (even without records)
Document symptoms and timelines
Preserve prescriptions and pharmacy history
Follow medical care and specialist recommendations

➡️ Start review: File a Claim
➡️ Symptom guide: Documenting Symptoms

Current GLP-1 Lawsuit Status (2026)